NeoGenomics (NASDAQ:NEO) COO Warren Stone Sells 22,128 Shares

NeoGenomics, Inc. (NASDAQ:NEO) COO Warren Stone sold 22,128 shares of NeoGenomics stock in a transaction dated Tuesday, January 20th. The stock was sold at an average price of $12.50, for a total value of $276,600.00. Following the sale, the chief operating officer directly owned 121,631 shares in the company, valued at approximately $1,520,387.50. The trade was a 15.39% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.

NeoGenomics Price Performance

Shares of NASDAQ NEO opened at $12.69 on Thursday. NeoGenomics, Inc. has a fifty-two week low of $4.72 and a fifty-two week high of $15.32. The business has a 50 day moving average price of $11.98 and a two-hundred day moving average price of $9.36. The company has a quick ratio of 3.62, a current ratio of 3.91 and a debt-to-equity ratio of 0.41. The firm has a market cap of $1.64 billion, a PE ratio of -14.42 and a beta of 1.58.

NeoGenomics (NASDAQ:NEO) last announced its earnings results on Tuesday, October 28th. The medical research company reported $0.03 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.02 by $0.01. The company had revenue of $187.80 million for the quarter, compared to analyst estimates of $183.85 million. NeoGenomics had a negative return on equity of 3.36% and a negative net margin of 16.00%.NeoGenomics’s quarterly revenue was up 12.0% on a year-over-year basis. During the same period in the prior year, the company posted $0.05 EPS. NeoGenomics has set its FY 2025 guidance at 0.080-0.120 EPS. Sell-side analysts expect that NeoGenomics, Inc. will post -0.2 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have weighed in on NEO. Needham & Company LLC reissued a “buy” rating and set a $14.00 price objective on shares of NeoGenomics in a report on Monday, January 12th. TD Cowen reaffirmed a “buy” rating on shares of NeoGenomics in a research report on Wednesday, January 7th. Leerink Partners set a $14.00 price objective on NeoGenomics in a report on Tuesday, October 28th. Weiss Ratings reissued a “sell (d-)” rating on shares of NeoGenomics in a report on Monday, December 29th. Finally, Zacks Research raised NeoGenomics from a “hold” rating to a “strong-buy” rating in a report on Monday, January 12th. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, NeoGenomics presently has an average rating of “Hold” and an average target price of $12.00.

Hedge Funds Weigh In On NeoGenomics

Large investors have recently bought and sold shares of the business. First Light Asset Management LLC grew its holdings in shares of NeoGenomics by 45.0% during the third quarter. First Light Asset Management LLC now owns 9,927,269 shares of the medical research company’s stock valued at $76,639,000 after purchasing an additional 3,080,837 shares during the last quarter. Greenhouse Funds LLLP boosted its position in NeoGenomics by 10.6% during the 3rd quarter. Greenhouse Funds LLLP now owns 8,220,657 shares of the medical research company’s stock valued at $63,463,000 after purchasing an additional 789,510 shares during the period. American Century Companies Inc. grew its stake in NeoGenomics by 6.0% during the 2nd quarter. American Century Companies Inc. now owns 3,517,478 shares of the medical research company’s stock worth $25,713,000 after buying an additional 197,876 shares during the last quarter. Geode Capital Management LLC increased its position in NeoGenomics by 0.8% in the second quarter. Geode Capital Management LLC now owns 3,156,621 shares of the medical research company’s stock worth $23,078,000 after buying an additional 26,224 shares during the period. Finally, Segall Bryant & Hamill LLC increased its position in NeoGenomics by 0.5% in the second quarter. Segall Bryant & Hamill LLC now owns 2,362,049 shares of the medical research company’s stock worth $17,267,000 after buying an additional 11,303 shares during the period. Institutional investors own 98.50% of the company’s stock.

About NeoGenomics

NeoGenomics, traded on the Nasdaq under the symbol NEO, is a leading provider of cancer-focused genetic and molecular testing services. Headquartered in Fort Myers, Florida, the company operates an integrated network of CAP-accredited and CLIA-certified laboratories across the United States, Europe and Asia. NeoGenomics delivers diagnostic insights that support oncologists, pathologists and healthcare institutions in the detection, prognosis and treatment of hematologic and solid tumor cancers.

The company’s core service offerings include flow cytometry, immunohistochemistry, fluorescence in situ hybridization (FISH), karyotyping and advanced molecular assays such as next-generation sequencing (NGS) panels and polymerase chain reaction (PCR) tests.